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b Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, GermanyChronic hepatitis E virus (HEV) infection in immunosuppressed pa- HEV infected patients (0.12%). The ﬁnding is remarkable considering
tients is increasingly recognized as a relevant clinical problem in
European countries. However, it is unclear whether chronic hepatitis E
is also a potential problem in eastern Asia. The study by lInagaki et al.
published in this issue of EBioMedicine is therefore of major interest
(Inagaki et al., 2015). The authors performed a large multi-center
study examining the frequency and clinical relevance of chronic hepati-
tis E in Japanese liver transplant recipients. About 75% of all liver trans-
plant centers participated in this study, comprising HEV-RNA testing of
1651 liver transplant recipients. Of note and very importantly, only two
chronic HEV infectionswere detected,which is a surprisingly low rate ofDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.09.030.
⁎ Corresponding author.
Fig. 1. Chronic hepatitis E in Japanese liver transplant recipien
http://dx.doi.org/10.1016/j.ebiom.2015.11.013
2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article underthat the median time from transplantation was 81 months (range 0–
297 months) representing a long time of potential exposure post-
transplantation.
The ﬁndings in Japan are quite different from European experiences
where many studies describe frequencies of chronic hepatitis E of more
than 1% in liver transplant cohorts (Fig. 1) (Behrendt et al., 2014). In
contrast, no case of chronic hepatitis E was found in India in a study
on 205 renal transplant recipients (Naik et al., 2013). This has led to
the hypothesis that HEV genotype 1, which is common in India, may
not cause chronic infection. However, most reported cases of chronicts is less common than in Europe (Behrendt et al., 2014).
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rarely HEV genotype 4. In Japan, HEV genotypes 3 and 4 are endemic
(Okano et al., 2014). The HEV subtype 3e is most frequently found in
Japan (Okano et al., 2014), as in Central Europe. HEV genotypes or sub-
types are therefore unlikely to explain the apparent differences in
chronic HEV frequencies — even though it is still possible that distinct
HEV strains circulating in Japan may be less likely to cause chronicity.
What then could explain the very low frequency of chronic hepatitis
E in Japan (Fig. 1)? First, it is possible that distinct genetic factors in
the Japanese population confer some level of resistance to chronic
HEV infection. For other infections such as hepatitis C, differences in
interferon-lambda 3 genotypes between Asians and Caucasians indeed
explain, to some extent, distinct outcomes in these populations
(Thursz et al., 2011). Second, there are obvious differences in food con-
sumption habits between Japan and Europe. Regarding HEV infection,
food products containing raw or undercooked pork meat are particular
popular in some European countries and thus exposure to HEV may be
more likely. Third, blood products may be less likely to carry HEV in
Japan than in Europe (Hewitt et al., 2014). Of note, HEV-IgG antibodies
have been shown to be lower in Japan (6%) than in Korean Chinese
(51%), indigenous Chinese (48%), SouthKoreans (34%) or Koreans living
in Japan (14%) (Taniguchi et al., 2009).In summary, Inagaki et al. demonstrated for theﬁrst time that chron-
ic hepatitis E also occurs in Japan, albeit at a far lower frequency than in
European transplant cohorts. The explanation for this difference still
needs to be deﬁned.References
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